On a preliminary basis, Hologic (NASDAQ:HOLX) expects FQ1 revenues of ~$850.5M (+2%). Breast health and Diagnostics should account for $331.1M (+2%) and $311.5M (+5%), respectively.
Board OKs new $500M share buyback program.
It will provide updated 2020 guidance when it reports final FQ1 results.
#JPM20
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.